ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0670

Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study

Sara Tedeschi1, Kazuki Yoshida1, Weixing Huang2 and Daniel H. Solomon1, 1Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 2Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston

Meeting: ACR Convergence 2020

Keywords: CPPD, Crystal-induced arthritis, pseudogout

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Metabolic & Crystal Arthropathies Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Prior studies of calcium pyrophosphate crystal deposition disease (CPPD) epidemiology either focused on the entire spectrum of CPPD or identified patients with its acute manifestation, pseudogout, using single non-validated diagnosis codes. We investigated previously identified risk factors for CPPD or pseudogout—including bisphosphonates, diuretics, osteoarthritis, and hyperparathyroidism—among well-defined pseudogout patients.

Methods: We performed a case-control study by applying a validated algorithm to identify pseudogout cases using electronic medical record (EMR) data (PPV 81%) at an academic medical center. Case index date was the earlier of 1st positive synovial fluid calcium pyrophosphate crystal analysis or 1st natural language processing concept “pseudogout” in narrative notes. Cases were matched to up to 4 general EMR controls not classified as pseudogout by the algorithm. Matching occurred on year of 1st EMR encounter and index date (encounter ±30d of case index date). We required age ≥50 at index date and ≥2 encounters in the 365 days before index date for cases and controls. We pre-specified covariates of interest: (1) comorbidities previously associated with CPPD in the literature, identified by ≥1 billing code from 1st EMR encounter through index date and (2) prescriptions for medications previously associated with CPPD in the literature, recorded in the 90 days prior to and including index date. A multimorbidity score was calculated for each patient using a validated method based on billing codes for 40 conditions. A multivariable logistic regression model estimated the odds ratio (OR) and 95% CI for each pre-specified covariate adjusted for age, total number of encounters from 1st EMR encounter through index date, multimorbidity score, and all pre-specified covariates.

Results: We identified 1856 cases matched to 7180 controls. Mean age was 73 years, 56.0% were female, 80.6% white, 10.2% black, and 9.2% other/unknown race. Among pseudogout patients, 12.8% were age 50-59, 25.9% age 60-69, 31.7% age 70-79, and 29.6% age ≥80. Each of the pre-specified covariates were more common in pseudogout cases than controls (Table). Risk for pseudogout was significantly higher for patients with osteoarthritis (OR 3.92), male sex (OR 1.42), proton pump inhibitors (OR 2.00), loop diuretics (OR 1.75), thiazides (OR 1.38), and rare metabolic disorders including hyperparathyroidism, hypomagnesemia, and hemochromatosis. Bisphosphonates were not significantly associated with pseudogout. Black race was associated with significantly lower risk for pseudogout compared to white race (OR 0.53).

Conclusion: Using a validated algorithm to identify >1800 pseudogout cases, we identified important metabolic correlates of this acute manifestation of CPPD. This is the first study to report higher risk for pseudogout among men and lower risk among black compared to white patients. We confirmed several previously published risk factors, but in contrast to prior studies we did not identify an association between bisphosphonates and pseudogout.


Disclosure: S. Tedeschi, None; K. Yoshida, OM1, 1, Corrona, 1; W. Huang, None; D. Solomon, Abbvie, 2, Amgen, 2, Genentech, 2, Janssen, 2, Corrona, 2, UpToDate, 7.

To cite this abstract in AMA style:

Tedeschi S, Yoshida K, Huang W, Solomon D. Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/risk-factors-for-pseudogout-an-electronic-medical-record-case-control-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-pseudogout-an-electronic-medical-record-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology